Change Of CD4⁺CD25⁺CD127^low/- Regulation T Cells In The Advanced Gastric Cancer Before And After Chemotherapy

Purpose:To study the change of the expression level of CD4+CD25+CD127low/-regulatory T cells(Treg) in peripheral blood from advanced gastric cancer patients before and after chemotherapy, and discuss the significance of the change in predicting chemotherapeutic effect.Methods:To select advanced or relapse metastasis of 30 patients who were pathological diagnosed with initially unresectable gastric cancer in our hospital from May,2013 to October, 2014, exclusion of patients with brain metastases or intestinal obstruction,which were experimental group. To select 10 healthy volunteers in our hospital in the same time, which were normal group. The expression level of CD4+CD25+CD127low/-regulatory T cells in peripheral blood from 30 advanced gastric cancer patients and 10 healthy volunteers was examined by flow cytometry(FCM).Results:1.The population of CD4+CD25+CD127low/- regulatory T cells in peripheral blood from advanced gastric cancer patients accounted for(10.41±2.85)% of CD4+T lymphocytes, and was significantly higher than those from healthy volunteers(5.05±1.32)%(t=8.04, P<0.01).2.There was no relationship between the expression level of CD4+CD25+CD127low/- regulatory T cells in peripheral blood from advanced gastric cancer patients and their gender, age, gastric cancer related tumor antigens(CEA and CA-199) and the site of the tumor(P>0.05), there was no significant variations between the expression level of CD4+CD25+CD127low/- regulatory T cells in peripheral blood from poorly differentiated group and those from moderately differentiated group(P>0.05).3.The population of CD4+CD25+CD127low/- regulatory T cells in peripheral bloodfrom advanced gastric cancer patients before chemotherapy accounted for(10.41±2.85)% of CD4+T lymphocytes, was significantly higher than those from advanced gastric cancer patients after 2 cycles of chemotherapy(7.07±1.45)%(t=5.72,P<0.01), and was also significantly higher than those from advanced gastric cancer patients after 4 cycles of chemotherapy(7.30±1.65)%(t=5.17, P<0.01).4.The population of CD4+CD25+CD127low/- regulatory T cells in peripheral blood from advanced gastric cancer patients after 2 cycles of chemotherapy accounted for(7.07±1.45)% of CD4+T lymphocytes, and there was no significant variations than those from advanced gastric cancer patients after 4 cycles of chemotherapy(7.30±1.65)%( t= 0.57, P>0.05).5.The population of CD4+CD25+CD127low/- regulatory T cells in peripheral blood from advanced gastric cancer patients after 2 cycles of combined chemotherapy with three trugs accounted for(6.87±1.66)% of CD4+T lymphocytes, and there was no significant variations than those from advanced gastric cancer patients after 2 cycles of combined chemotherapy with two trugs(7.21±1.33)%( t= 0.61, P>0.05).6.The population of CD4+CD25+CD127low/-regulatory T cells in peripheral blood from advanced gastric cancer patients who were remission group after 2 cycles of chemotherapy accounted for(6.25±1.08)% of CD4+T lymphocytes and those from advanced gastric cancer patients who were no-remission group after 2 cycles of chemotherapy accounted for(7.98±1.27)%, there was difference between the remission group and the no-remission group( t= 4.02, P<0.01).Conclusions:The decrease of the expression level of CD4+CD25+CD127low/- regulatory T cells in peripheral blood from advanced gastric cancer patients was associated with chemotherapeutic effect.